These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20067905)

  • 1. Glomerulonephritis after hematopoietic cell transplantation: IgA nephropathy with increased excretion of galactose-deficient IgA1.
    Hu SL; Colvin GA; Rifai A; Suzuki H; Novak J; Esparza A; Farooqi S; Julian BA
    Nephrol Dial Transplant; 2010 May; 25(5):1708-13. PubMed ID: 20067905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomerular galactose-deficient IgA1 expression analysis in pediatric patients with glomerular diseases.
    Ishiko S; Horinouchi T; Fujimaru R; Shima Y; Kaito H; Tanaka R; Ishimori S; Kondo A; Nagai S; Aoto Y; Sakakibara N; Nagano C; Yamamura T; Yoshimura M; Nakanishi K; Fujimura J; Kamiyoshi N; Nagase H; Yoshikawa N; Iijima K; Nozu K
    Sci Rep; 2020 Aug; 10(1):14026. PubMed ID: 32820208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
    Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
    Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
    Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
    Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
    PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Galactose-Deficient IgA1 Derived From the Tonsils and Recurrence of IgA Nephropathy in Patients Who Underwent Kidney Transplantation.
    Kawabe M; Yamamoto I; Yamakawa T; Katsumata H; Isaka N; Katsuma A; Nakada Y; Kobayashi A; Koike K; Ueda H; Tanno Y; Koike Y; Miki J; Yamada H; Kimura T; Ohkido I; Tsuboi N; Yamamoto H; Kojima H; Yokoo T
    Front Immunol; 2020; 11():2068. PubMed ID: 33013875
    [No Abstract]   [Full Text] [Related]  

  • 7. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
    Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
    Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression.
    Elíasdóttir S; Khramova A; Saeed A; Guron G; Boi R; Mölne J; Ebefors K; Nyström J
    BMC Nephrol; 2023 Jun; 24(1):160. PubMed ID: 37286948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Biomarker for Post-Transplant Recurrent IgA Nephropathy.
    Temurhan S; Akgul SU; Caliskan Y; Artan AS; Kekik C; Yazici H; Demir E; Caliskan B; Turkmen A; Oguz FS; Sever MS
    Transplant Proc; 2017 Apr; 49(3):541-545. PubMed ID: 28340830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
    J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.
    Lee M; Suzuki H; Kato R; Fukao Y; Nakayama M; Kano T; Makita Y; Suzuki Y
    CEN Case Rep; 2021 Feb; 10(1):17-22. PubMed ID: 32676896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
    Zhang X; Xie X; Shi S; Liu L; Lv J; Zhang H
    Nephrol Dial Transplant; 2020 Dec; 35(12):2117-2123. PubMed ID: 31377786
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Liu XZ; Zhang YM; Jia NY; Zhang H
    Ren Fail; 2020 Nov; 42(1):539-546. PubMed ID: 32524871
    [No Abstract]   [Full Text] [Related]  

  • 14. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.
    Zhao N; Hou P; Lv J; Moldoveanu Z; Li Y; Kiryluk K; Gharavi AG; Novak J; Zhang H
    Kidney Int; 2012 Oct; 82(7):790-6. PubMed ID: 22673888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
    Stuchlova Horynova M; Vrablikova A; Stewart TJ; Takahashi K; Czernekova L; Yamada K; Suzuki H; Julian BA; Renfrow MB; Novak J; Raska M
    Nephrol Dial Transplant; 2015 Feb; 30(2):234-8. PubMed ID: 25281698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
    Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
    PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
    Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
    Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crescentic IgA nephropathy after administration of human monoclonal interleukin-12/23p40 antibody in a patient with Crohn's disease: a case report.
    Kanazawa N; Wada Y; Akiyama M; Shikida Y; Sugiyama M; Abe M; Iyoda M; Honda K; Shibata T
    CEN Case Rep; 2020 Aug; 9(3):204-209. PubMed ID: 32100251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.
    Wang M; Lv J; Chen P; Yu G; Shi S; Liu L; Zhou X; Xu D; Zhao M; Zhang H
    Nephrol Dial Transplant; 2021 Jan; 36(2):288-294. PubMed ID: 31603230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
    Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
    PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.